Page 93 - Sohini Das

Govt revises PLI scheme for bulk drugs to boost local manufacturing

Industry says revised PLI scheme will attract more MSMEs to invest as minimum investment clause done away with

Syringe, vial makers ramp up capacity amid Covid-19 vaccine hopes

The first of a two-part series looks at the ways in which the supply chain for the delivery of the Covid-19 vaccine is being bolstered

Covid-19: Dr Reddy's engages Indian partners to develop Sputnik V

Sputnik V is also undergoing Phase 3 clinical trials in Russia and other parts of the globe on 40,000 volunteers

Aurobindo Pharma to sell US-based Natrol for about Rs 4,048 crore

Aurobindo's stock reacted positively to the news, going up in morning trade but later settled flat at Rs 784.65 on the BSE

Investigational therapy: Ozone next in the mix to help fight Covid-19

It has the potential of an immunity-boosting prophylactic and can help ease post-Covid-19 complications

Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Covid-19: Bharat Biotech cuts Covaxin phase-2 clinical trial size by half

For phase-2 studies, the firm is also testing the vaccine on children above 12 years of age. In phase-1, they only tested adults.

Indian samples of global Covid-19 vaccines need to be larger: Experts

Indian players like Bharat Biotech and Zydus Cadila ready for large-scale phase-3 trials

Smaller pharma firms post faster domestic sales growth in September

Barring Cipla and Glenmark, whose sales have grown in double digits due to demand for their Covid-19 drugs like favipiravir, tocilizumab, most big players have posted tepid growth

Govt begins micro-planning for administering Covid-19 vaccine to the masses

Centre has asked states to update databases, train manpower, indicate resource requirements

We can make over 1.5 bn doses in 2021: Biological E MD & CEO Mahima Datla

Though our target is a billion doses, we may have an upside as we are evaluating various doses in the phase-1 and -2 studies, said Datla

Immunity hurdle for a shot at Covid vaccine; govt working on priority list

Rapid antibody tests at dedicated Covid-19 vaccination centres to act as screening tool

Piramal Pharma readies war chest for potential acquisition targets

A decade after Piramal sold its domestic formulations business to Abbott Laboratories for $3.72 billion, the group is now looking at re-entering the space in India

Cardiac, vitamin drugs see pharma sales rebound with 4.5% growth in Sept

Industry says fresh prescriptions are picking up

Covid-19 vaccine: Bharat Biotech to use Kansas firm's adjuvant for Covaxin

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

With phase 4 clinical trials now on, the sales may see a further uptick if data supports its use on Covid-19 patients, said experts.

Indigenous players on a slow and steady coronavirus vaccine race

Smaller players are bullish on playing crucial role in nation's vaccine infrastructure

Patented molecules clock a high growth rate in Indian cardiovascular market

In January 2020, the Delhi High Court granted an injunction restraining domestic companies such as Cipla, Torrent, Emcure, and Alkem from launching their brands

Covid-19: 8% super-spreaders account for 60% new infections, says study

The findings are part of a survey conducted by the Center For Disease Dynamics, Economics & Policy (CDDEP) along with governments of Tamil Nadu and Andhra Pradesh

Revised, more industry-friendly PLI scheme for bulk drugs on the cards

Industry says move will mean lower spends and reduced dependence on China